Cumberland Pharmaceuticals Files 8-K on Financials
Ticker: CPIX · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1087294
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: CPRX
TL;DR
CPRX dropped an 8-K detailing financials - check it out.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on August 6, 2024, to report on its financial condition and results of operations. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with crucial updates on Cumberland Pharmaceuticals' financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate indication of significant new risks.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
- August 6, 2024 (date) — Date of Report
- 2525 WEST END AVENUE (address) — Business Address
- NASHVILLE, TN (location) — Business Address City/State
- 615-255-0068 (phone) — Business Phone
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not provided in the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the Results of Operations and Financial Condition of Cumberland Pharmaceuticals Inc.
When was this 8-K filing submitted?
This 8-K filing was submitted on August 6, 2024.
What is Cumberland Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-06 17:07:25
Filing Documents
- cpix-20240806.htm (8-K) — 28KB
- a2024q2-ex991er.htm (EX-99.1) — 235KB
- cumberlandpharmaimageaa06a.jpg (GRAPHIC) — 37KB
- 0001628280-24-035262.txt ( ) — 459KB
- cpix-20240806.xsd (EX-101.SCH) — 2KB
- cpix-20240806_lab.xml (EX-101.LAB) — 21KB
- cpix-20240806_pre.xml (EX-101.PRE) — 12KB
- cpix-20240806_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and six months ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release dated August 6, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: August 6, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer